BRPI0716145A2 - formuaÇço de vacina, mÉtodo de adaptaÇço e propagaÇço do vÍrus chikungunya, mÉtodo de concentraÇço e purificaÇço de vÍrus, composiÇço potencialmente imunogÊnica, sequÊncia de nucleotÍdeo, contruto de dna recombinante, mÉtodo para produzir proteÍna recombinante, composiÇço farmacÊutica, mÉtodo in vitro ou in vivo e mÉtodo para elicitar resposta imune protetora - Google Patents

formuaÇço de vacina, mÉtodo de adaptaÇço e propagaÇço do vÍrus chikungunya, mÉtodo de concentraÇço e purificaÇço de vÍrus, composiÇço potencialmente imunogÊnica, sequÊncia de nucleotÍdeo, contruto de dna recombinante, mÉtodo para produzir proteÍna recombinante, composiÇço farmacÊutica, mÉtodo in vitro ou in vivo e mÉtodo para elicitar resposta imune protetora

Info

Publication number: BRPI0716145A2
Authority: BR; Brazil
Prior art keywords: vitro; composition; nucleotide sequence; immune response; dna construct
Prior art date: 2006-09-01

Application number

BRPI0716145-0A2A

Other languages

English (en)

Inventor

Krishna Murthy Ella

Kandaswamy Sumathy

Jaya Sheela Pydigummala

Nagendra R Hedge

Original Assignee

Bharat Biotech Int Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-09-01

Filing date

2007-08-31

Publication date

2013-09-17

2007-08-31 Application filed by Bharat Biotech Int Ltd filed Critical Bharat Biotech Int Ltd

2013-09-17 Publication of BRPI0716145A2 publication Critical patent/BRPI0716145A2/pt

2021-06-22 Publication of BRPI0716145B1 publication Critical patent/BRPI0716145B1/pt

Links

238000000338 in vitro Methods 0.000 title 3
238000000034 method Methods 0.000 title 3
239000000203 mixture Substances 0.000 title 3
241001502567 Chikungunya virus Species 0.000 title 1
108020004511 Recombinant DNA Proteins 0.000 title 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 title 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 title 1
241000700605 Viruses Species 0.000 title 1
230000006978 adaptation Effects 0.000 title 1
238000009472 formulation Methods 0.000 title 1
230000028993 immune response Effects 0.000 title 1
230000002163 immunogen Effects 0.000 title 1
238000001727 in vivo Methods 0.000 title 1
238000004519 manufacturing process Methods 0.000 title 1
239000002773 nucleotide Substances 0.000 title 1
125000003729 nucleotide group Chemical group 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
230000001681 protective effect Effects 0.000 title 1
238000000746 purification Methods 0.000 title 1
229960005486 vaccine Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36151—Methods of production or purification of viral material
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36161—Methods of inactivation or attenuation
- C12N2770/36163—Methods of inactivation or attenuation by chemical treatment
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Virology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Immunology (AREA)
Microbiology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Molecular Biology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Mycology (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

BRPI0716145-0A 2006-09-01 2007-08-31 Composição de vacina e método para preparar uma composição de vacina para o vírus chikungunya BRPI0716145B1 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
IN1583CH2006		2006-09-01
IN1583/CHE/2006		2006-09-01
PCT/IN2007/000383 WO2008026225A2 (en)	2006-09-01	2007-08-31	A vaccine for chikungunya virus infection

Publications (2)

Publication Number	Publication Date
BRPI0716145A2 true BRPI0716145A2 (pt)	2013-09-17
BRPI0716145B1 BRPI0716145B1 (pt)	2021-06-22

Family

ID=39136377

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0716145-0A BRPI0716145B1 (pt)	2006-09-01	2007-08-31	Composição de vacina e método para preparar uma composição de vacina para o vírus chikungunya

Country Status (5)

Country	Link
US (1)	US8865184B2 (pt)
EP (1)	EP2073839B1 (pt)
CN (1)	CN101516395B (pt)
BR (1)	BRPI0716145B1 (pt)
WO (1)	WO2008026225A2 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2545597A1 (en) *	2006-03-15	2007-09-15	Institut Pasteur	Novel isolated and purified strains of chikungunya virus and polynucleotides and polypeptides sequences, diagnostic and immunogenical uses thereof
CA2598966A1 (en) *	2007-09-07	2009-03-07	Institut Pasteur	Anti-chikungunya monoclonal antibodies and uses thereof
JP5744719B2 (ja) *	2008-04-04	2015-07-08	ザトラスティーズオブザユニバーシティオブペンシルバニア	チクングニヤウィルスタンパク質の共通配列、これをコードする核酸分子、並びにこれを使用する組成物および方法
EP2281070B1 (en)	2008-04-21	2015-01-21	Gen-Probe Incorporated	Method for detecting chikungunya virus
CN107574156A (zh)	2008-11-26	2018-01-12	美国国有健康与人类服务部	类病毒组合物颗粒及其使用方法
US9101572B2 (en) *	2009-12-31	2015-08-11	Medigen, Inc.	Infectious DNA vaccines against chikungunya virus
US9441032B2 (en)	2010-04-07	2016-09-13	Agency For Science, Technology And Research	Binding molecules against Chikungunya virus and uses thereof
EP2374816B1 (en) *	2010-04-07	2016-09-28	Agency For Science, Technology And Research	Binding molecules against Chikungunya virus and uses thereof
JP2013523175A (ja) *	2010-04-14	2013-06-17	イーエムディー・ミリポア・コーポレーション	高力価、高純度のウイルスストックの作製方法及びその使用方法
CN103228293A (zh) *	2010-11-30	2013-07-31	巴拉特生物技术国际有限公司	用于在哺乳动物中预防和治疗金迪普拉病毒感染的疫苗制剂
CN103476788A (zh) *	2010-12-10	2013-12-25	新加坡科技研究局	免疫原性屈曲病毒肽
WO2012172574A1 (en)	2011-06-17	2012-12-20	Bharat Biotech International Limited	Vaccine composition comprising an inactivated chikungunya virus strain
EP2968515B1 (en) *	2013-03-14	2019-05-08	Takeda Vaccines, Inc.	Compositions and methods for live, attenuated alphavirus formulations
MA41517A (fr) *	2015-04-14	2017-12-19	Univ Vanderbilt	Neutralisation du virus du chikungunya à médiation par des anticorps
MY187459A (en) *	2015-07-16	2021-09-23	Bharat Biotech Int Ltd	Vaccine compositions
EP4253403A3 (en) *	2015-12-23	2023-12-27	Valneva Austria GmbH	Zika virus purification
WO2017123932A1 (en) *	2016-01-13	2017-07-20	United States, As Represented By The Secretary Of The Army	Inactived vaccine for chikungunya virus
SG11201808458QA (en)	2016-03-31	2018-10-30	Takeda Vaccines Inc	Compositions and methods for stabilizing alphaviruses with improved formulations
CN105906694B (zh) *	2016-05-05	2019-05-14	中国人民解放军军事医学科学院微生物流行病研究所	基孔肯亚病毒特异性检测抗原及其应用
AU2017261705B2 (en)	2016-05-10	2024-04-18	Najit Technologies, Inc.	Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production
WO2017210215A1 (en)	2016-05-31	2017-12-07	The Government Of The United States Of America As Represented By The Secretary Of The Army	Zika virus vaccine and methods of production
US11273215B2 (en) *	2017-07-03	2022-03-15	Bharat Biotech International Limited	Synthetic polypeptide epitope based vaccine composition
SG11202001161YA (en)	2017-09-21	2020-03-30	Valneva Se	Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus chikv-delta5nsp3
CA3081581A1 (en)	2017-11-03	2019-05-09	Takeda Vaccines, Inc.	Method for inactivating zika virus and for determining the completeness of inactivation
AU2018375173B2 (en)	2017-11-30	2022-08-25	Takeda Vaccines, Inc.	Zika vaccines and immunogenic compositions, and methods of using the same
US10718771B2 (en)	2018-02-09	2020-07-21	Chung Yuan Christian University	Recombinant baculoviruses and their uses in detecting arthropod-borne virus
EP3755709A1 (en)	2018-02-22	2020-12-30	Euroimmun Medizinische Labordiagnostika AG	Assay for the diagnosis of viral infections
EP3530668A1 (en)	2018-02-22	2019-08-28	Euroimmun Medizinische Labordiagnostika AG	A novel assay for the diagnosis of viral infections
CA3137652A1 (en) *	2019-05-08	2020-11-12	Takeda Vaccines, Inc.	Inactivated virus compositions and zika vaccine formulations
US11519919B2 (en)	2019-07-02	2022-12-06	Euroimmun Medizinische Labordiagnostika Ag	Assay for the diagnosis of nematode infections
EP4048306A4 (en) *	2019-10-25	2024-03-27	Bavarian Nordic A/S	CHIKUNGUNYA VIRUS PARTICLE VACCINE AND METHODS OF USE THEREOF
CN117771353B (zh) *	2024-02-27	2024-05-14	中国医学科学院医学生物学研究所	一种以包膜蛋白为靶标的基孔肯雅病毒的mRNA疫苗及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1248471A (zh) *	1998-09-23	2000-03-29	卫生部北京生物制品研究所	Vero细胞乙型脑炎灭活疫苗及其制备方法
WO2008030220A2 (en) *	2005-08-11	2008-03-13	The Board Of Regents Of The University Of Texas System	Chikungunya virus infectious clones and uses thereof
CA2545597A1 (en) *	2006-03-15	2007-09-15	Institut Pasteur	Novel isolated and purified strains of chikungunya virus and polynucleotides and polypeptides sequences, diagnostic and immunogenical uses thereof

2007
- 2007-08-31 US US12/439,509 patent/US8865184B2/en active Active
- 2007-08-31 CN CN200780035576.XA patent/CN101516395B/zh active Active
- 2007-08-31 WO PCT/IN2007/000383 patent/WO2008026225A2/en not_active Ceased
- 2007-08-31 BR BRPI0716145-0A patent/BRPI0716145B1/pt active IP Right Grant
- 2007-08-31 EP EP07827554.2A patent/EP2073839B1/en active Active

Also Published As

Publication number	Publication date
CN101516395A (zh)	2009-08-26
WO2008026225A3 (en)	2008-09-25
CN101516395B (zh)	2014-03-26
EP2073839A2 (en)	2009-07-01
BRPI0716145B1 (pt)	2021-06-22
US20130022631A1 (en)	2013-01-24
EP2073839B1 (en)	2016-10-19
WO2008026225A2 (en)	2008-03-06
US8865184B2 (en)	2014-10-21

Similar Documents

Publication	Publication Date	Title
BRPI0716145A2 (pt)	2013-09-17	formuaÇço de vacina, mÉtodo de adaptaÇço e propagaÇço do vÍrus chikungunya, mÉtodo de concentraÇço e purificaÇço de vÍrus, composiÇço potencialmente imunogÊnica, sequÊncia de nucleotÍdeo, contruto de dna recombinante, mÉtodo para produzir proteÍna recombinante, composiÇço farmacÊutica, mÉtodo in vitro ou in vivo e mÉtodo para elicitar resposta imune protetora
MX2014004214A (es)	2014-05-07	Moleculas de acido ribonucleico policistronicas auto-replicantes recombinantes.
BR112015005987A2 (pt)	2017-08-08	vacina, métodos para induzir uma resposta imune contra um antígeno hbv, para proteção de um sujeito da infeção por hbv, para proteger o sujeito que foi diagnosticado com uma infecção por hbv, para induzir uma resposta imune contra um antígeno do hbv, para proteger um indivíduo da infecção pelo hbv, para proteger um indivíduo que foi diagnosticado com infecção pelo hbv, para proteger um indivíduo da infecção pelo hbv, para proteger um indivíduo que foi diagnosticado com infecção pelo hbv, para proteger um sujeito contra infecção por hbv e para proteger o sujeito que foi diagnosticado com uma infecção por hbv, molécula de ácido nucleico, e, proteína
WO2010066418A8 (de)	2010-08-12	Verwendung von flt3-ligand zur verstärkung von immunreaktionen bei rna-immunisierung
EP2069376A4 (en)	2013-10-16	INDUCTION OF CELLULAR IMMUNE RESPONSES TO INFLUENZA VIRUS BY COMPOSITIONS OF PEPTIDES AND NUCLEIC ACIDS
BR112014015016A8 (pt)	2023-05-09	Proteína homodimérica de duas cadeias de aminoácidos idênticas, cadeia de aminoácido, molécula de ácido nucléico, composição farmacêutica, célula hospedeira, método de preparação de uma proteína homodimérica, método para preparação de uma vacina, vacina e método de tratamento ou prevenção
WO2012069655A3 (en)	2012-07-19	Improved capping modules for designed ankyrin repeat proteins
DK2154990T3 (da)	2013-10-07	Funktionelt serumproteinprodukt til anvendelse i spædbørnsernæring samt terapeutiske sammensætninger og fremgangsmåder til deres fremstilling
AR077757A1 (es)	2011-09-21	Composiciones de proteinas de fusion del virus sincicial respiratorio (rsv) y metodos para su preparacion
BRPI0811193A2 (pt)	2014-11-11	Proteína de ligação a antígeno isolada, ácido nucleico, célula recombinante, métodos para produzir uma proteína e para proteger ou tratar contra uma infecção por s. aureus em paciente, composição farmacêutica, uso da proteína de ligação a antígeno, e, polipeptídeo.
IL180101A (en)	2014-02-27	Isolated peptides, peptide complex / mhc class – i, peptide-encoded nucleic acid sequences, immune-containing peptides or nucleic acid sequences and their use in drug preparation
BRPI0906997A2 (pt)	2015-07-07	Proteína, uso da proteína combinante ou fragmento da mesma, método para induzir uma resposta imune em um individuo, método para tratar um paceinte, construção de ácido nicleico, vetor de ezpressão o ucélula hospedeira, vacina, anticorpo, e, composição farmaceutica
BRPI1012078A2 (pt)	2019-09-24	construto de proteína, composição imunogênica, molécula de ácido nucleico , métodos de induzir uma resposta imune a casb7439 e de tratar um animal humano ou não-humano, e, uso de uma composição imunogênica
IN2012DN03209A (pt)	2015-10-23
AR079114A1 (es)	2011-12-28	Proteinas de enlace de antigenos anti-orai1 y usos de las mismas
BRPI0815578B8 (pt)	2023-01-03	Peptídeo de cdca1, seu uso e composição imunogênica compreendendo o mesmo para induzir imunidade, tratar e/ou prevenir o câncer, bem como método in vitro para induzir uma célula apresentadora de antígeno e uma célula t citotóxica (killer)
JP2011517938A5 (pt)	2012-05-31
BRPI0921424A2 (pt)	2016-01-05	vírus sincicial respiratório atenuado, composição imunogênica, molécula de ácido nucléico, célula recombinante, método para produzir uma resposta imune protetiva em um paciente, e, uso de uma quantidade imunologicamente eficaz de um ou mais dos seguintes: um rsv atenuado, uma população de rsv atenuado e uma composição imunogênica.
WO2014046622A1 (en)	2014-03-27	Novel attenuated dengue virus strains for vaccine application
BRPI0906044A2 (pt)	2015-07-07	"mutante solúvel tnfrp75, proteína de fusão, sequências de dna, usos do mutante solúvel tnfrp75 e da proteína de fusão e composições farmacêuticas"
EP1989316A4 (en)	2011-01-05	METHOD FOR THE PRODUCTION OF RECOMBINANT VIRUS, DNA CONSTRUCTS, RECOMBINANT VIRUS AND VACCINE COMPOSITIONS
WO2009074861A3 (en)	2009-12-17	Improved vaccine
WO2008027560A3 (en)	2008-09-18	Holin-enhanced vaccines and reagents, and methods of use thereof
WO2012003320A3 (en)	2012-05-18	Flavivirus host-range mutations and uses thereof
WO2009077744A3 (en)	2009-10-15	Vaccines for brucellosis

Legal Events

Date	Code	Title	Description
2017-03-21	B65X	Notification of requirement for priority examination of patent application
2017-04-11	B65Z	Priority examination of the patent application refused (request does not comply with dec. 132/06 of 20061117)
2018-04-24	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-06-25	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2020-05-19	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2020-08-25	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2021-02-02	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2021-05-18	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2021-06-22	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/08/2007, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, , QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.